What is the contrast media dosing that predicts acute kidney injury after TAVI?

Original title: Renal Function-Based Contrast Dosing Predicts Acute Kidney Following Trancatheter Aortic Valve Implantation Reference: Masanori Yamamoto, et al. J Am Coll Cardiol Intv 2013;6:479–86.

Acute kidney injury (AKI) presents in 10 to 30% of patients undergoing TAVI; it is associated to the increase of morbidity and mortality and it prolongues hospitalization. This study included 415 patients with severe aortic stenosis that received the Edwards Valve or the CoreValve

Renal function was estimated using the glomerular filtration rate (eGFR) value, and contrast media dosing (CM) was determined with the formula that calculates CM volume to serum creatinine (SCr) and body weight (BW) (CM × SCr/BW). 63 patients (15.2%) presented acute kidney injury (AKI), and 59 of them (93.7%) were categorized as grade 2.

AKI patients had a significantly lower eGRF, lower ejection fraction and higher aortic regurgitation degree. CM dosing was also higher. Mortality at 30 days was significantly higher among AKI patients (15.9% vs. 4.1%; p<0.001) as well as mortality at 12 months (47.9% vs. 15.7%; p<0.001). Vascular complications and transfusion rates were also higher in the AKI group. The cut-off point that predicts kidney failure in the formula that associates CM volume, creatinine and body weight is 2.7.

Conclusion:

Even though the mechanism that produces post TAVI kidney injury is multifactorial, this study identified the relationship between CM dosing and the prevalence of AKI.

Comment: 

Post TAVI AKI is multifactorial, especially in this group of patients. One of the factors to be considered is the risk of procedural hypotension, especially at the moment of valvuloplasty, since it could prolong and impact at kidney level, adding to CM impact. This study has given us the tools to assess renal impact and take the necessary steps to reduce the risk of AKI.

SOLACI.ORG

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...